In a move announced Sept. 5, Jason Hannon, until recently NuVasive’s president and COO, will take the reins as the CEO of Mainstay Medical International, a medical device company.
NuVasive in July announced that Hannon would step down to pursue other interests. During his 12-year tenure at NuVasive, in which his roles also included executive vice president of international and executive vice president of business development and strategy, the company’s commercial presence expanded globally to more than 40 countries and revenue grew from $61 million to $962 million.
Hannon will start as Mainstay’s CEO on Oct. 9, succeeding Peter Crosby, who is retiring. Mainstay, based in Dublin, Ireland, seeks to bring to market ReActiv8, an implantable restorative neurostimulation system to treat chronic low back pain.
“Mainstay has developed a strong foundation in its scientific, clinical and regulatory accomplishments to date,” Hannon said in a news release. “The dedicated team has done the pioneering work to establish a new market - ReActiv8 seeks to help the body repair itself rather than merely masking pain. This has created the potential of bringing an entirely new option to people suffering from chronic back pain. I am impressed by the work done to get to this point, and I look forward to working with the entire team to advance the mission.”